Not Medicare Enrolled
Dr. Vance Wright-Browne, M.D.
Hematology · Port Charlotte, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Wright-Browne from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wright-Browne? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wright-Browne
Dr. Vance Wright-Browne is a hematology in Port Charlotte, FL, with 20 years in practice. Based on federal Medicare data, Dr. Wright-Browne performed 239,407 Medicare services across 7,007 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wright-Browne received a total of $3,714 from 49 pharmaceutical and/or device companies across 202 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wright-Browne is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 14% volume in FL$ $3,714 industry payments
Medicare Practice Summary
Medicare Utilization ↗239,407
Medicare services
Top 14% in FL for hematology
7,007
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,970 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 59,160 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 23,200 | $43 | $137 |
| Iron sucrose injection (Venofer) | 22,200 | $0 | $5 |
| Anti-nausea injection (aprepitant) | 20,670 | $1 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 17,940 | $0 | $2 |
| Paclitaxel chemotherapy injection | 13,826 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 12,600 | $18 | $51 |
| Daratumumab injection (Darzalex) | 10,620 | $38 | $110 |
| Epoetin alfa injection (Procrit) for anemia | 8,838 | $6 | $23 |
| Immune globulin infusion (Gammagard) | 8,276 | $36 | $108 |
| Nivolumab injection (Opdivo) | 6,420 | $24 | $72 |
| Dexamethasone injection (steroid) | 3,781 | $0 | $3 |
| Blood draw (venipuncture) | 3,482 | $8 | $9 |
| Complete blood count (CBC) with differential | 3,383 | $8 | $29 |
| Injection, mepolizumab, 1 mg | 3,300 | $23 | $72 |
| Injection, bortezomib, 0.1 mg | 2,870 | $4 | $113 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,110 | $1 | $28 |
| Office visit, established patient (30-39 min) | 1,792 | $94 | $339 |
| Injection, fulvestrant, 25 mg | 1,740 | $9 | $132 |
| Infliximab infusion (Remicade) | 1,610 | $26 | $124 |
| Injection of additional new drug or substance into vein | 1,328 | $12 | $61 |
| Drug injection, under skin or into muscle | 1,085 | $10 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 992 | $0 | $9 |
| Administration of chemotherapy into vein, 1 hour or less | 692 | $97 | $378 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 537 | $47 | $189 |
| Injection, carboplatin, 50 mg | 522 | $2 | $41 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 421 | $17 | $59 |
| Injection, cisplatin, powder or solution, 10 mg | 396 | $2 | $13 |
| Injection, diphenhydramine hcl, up to 50 mg | 395 | $1 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 353 | $1 | $6 |
| Injection, fluorouracil, 500 mg | 331 | $2 | $7 |
| Administration of chemotherapy into vein, each additional hour | 308 | $21 | $79 |
| Injection, zoledronic acid, 1 mg | 276 | $6 | $69 |
| Injection, potassium chloride, per 2 meq | 270 | $0 | $4 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 264 | $84 | $642 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 262 | $15 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 233 | $55 | $206 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 217 | $3 | $11 |
| Office visit, established patient, complex (40-54 min) | 198 | $138 | $474 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 196 | $3 | $205 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 187 | $26 | $89 |
| Administration of additional new drug or substance into vein, 1 hour or less | 187 | $48 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 183 | $22 | $84 |
| Infusion into a vein for hydration, each additional hour | 182 | $10 | $42 |
| Office visit, established patient (20-29 min) | 151 | $62 | $239 |
| Injection, magnesium sulfate, per 500 mg | 148 | $1 | $2 |
| Infusion, normal saline solution , 1000 cc | 140 | $2 | $7 |
| Red blood count, automated test | 115 | $4 | $10 |
| New patient office visit (45-59 min) | 109 | $125 | $453 |
| Prothrombin time test (blood clotting) | 108 | $4 | $15 |
| Injection of drug or substance into vein | 105 | $28 | $156 |
| Infusion into a vein for hydration, 31-60 minutes | 87 | $24 | $156 |
| Automated urinalysis | 78 | $2 | $8 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 64 | $1 | $7 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 60 | $137 | $562 |
| Hospital follow-up visit, moderate complexity | 58 | $63 | $197 |
| Injection, furosemide, up to 20 mg | 50 | $0 | $9 |
| Administration of additional new drug or substance into vein using push technique | 45 | $42 | $170 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 45 | $4 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 43 | $15 | $56 |
| Drawing of blood for a medical problem | 37 | $64 | $277 |
| New patient office visit, complex (60-74 min) | 35 | $173 | $585 |
| Administration of chemotherapy into vein using push technique | 32 | $76 | $303 |
| Initial hospital admission, high complexity | 22 | $137 | $556 |
| Transitional care management services for problem of high complexity | 15 | $214 | $722 |
| Initial hospital admission, moderate complexity | 14 | $103 | $377 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $125 | $467 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.5% high complexity
66.2% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,714
Total received (2018-2024)
Avg $531/year across 7 years
Bottom 34% in FL for hematology
49
Companies
202
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,543 (95.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$170 (4.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$460
2023$546
2022$856
2021$741
2020$359
2019$454
2018$298
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$562
Janssen Biotech, Inc.
$454
Celgene Corporation
$278
Amgen Inc.
$189
Genentech USA, Inc.
$176
Daiichi Sankyo Inc.
$162
Gilead Sciences, Inc.
$150
AstraZeneca Pharmaceuticals LP
$132
PFIZER INC.
$122
Seagen Inc.
$121
Exelixis Inc.
$105
ABBVIE INC.
$85
GENZYME CORPORATION
$84
Novartis Pharmaceuticals Corporation
$81
Regeneron Healthcare Solutions, Inc.
$56
Janssen Scientific Affairs, LLC
$54
Incyte Corporation
$51
JAZZ PHARMACEUTICALS INC.
$51
Myovant Sciences Inc.
$48
EMD Serono, Inc.
$48
Merck Sharp & Dohme Corporation
$46
ARRAY BIOPHARMA INC
$45
BeiGene USA, Inc.
$44
Takeda Pharmaceuticals U.S.A., Inc.
$42
AbbVie Inc.
$40
NanoString Technologies, Inc.
$36
Astellas Pharma US Inc
$32
Karyopharm Therapeutics Inc.
$31
Stemline Therapeutics Inc.
$29
GlaxoSmithKline, LLC.
$29
Telix Pharmaceuticals
$25
Eisai Inc.
$23
GE HealthCare
$22
Dendreon Pharmaceuticals LLC
$22
Lilly USA, LLC
$22
Acrotech Biopharma Inc.
$21
Shire North American Group Inc
$20
EISAI INC.
$20
Merck Sharp & Dohme LLC
$19
Heron Therapeutics, Inc.
$18
AbbVie, Inc.
$18
PharmaEssentia USA Corporation
$18
G1 Therapeutics, Inc.
$15
TerSera Therapeutics LLC
$15
Sysmex Inostics Inc
$15
Bayer HealthCare Pharmaceuticals Inc.
$13
SANOFI-AVENTIS U.S. LLC
$13
Aurobindo Pharma USA, Inc.
$12
Veracyte, Inc.
$1
Top 3 companies account for 34.9% of total payments
Associated products mentioned in payments ›
Alecensa · Aliqopa · Avastin · BELEODAQ · BESREMI · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CEREZYME · COSELA · CYRAMZA · Cabometyx · DARZALEX · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Erleada · GAZYVA · ILLUCCIX · IMBRUVICA · INLYTA · KEYTRUDA · KISQALI · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · MONJUVI · NINLARO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROSIGNA ASSAY · PROVENGE · Perjeta · Phesgo · Pomalyst · REBLOZYL · RETACRIT · RYBREVANT · Revlimid · SARCLISA · SPRYCEL · SUSTOL · TAGRISSO · TECVAYLI · TIVDAK · Trodelvy · VARUBI · VENCLEXTA · VYXEOS · Venclexta · XALKORI · XPOVIO · XTANDI · Xospata · ZEJULA · ZEPZELCA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
10
Per 100K population
5.1
County median income
$66,154
Nearest hospital
Adventhealth Port Charlotte
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | — Not enrolled | N/A |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Wright-Browne is a mixed practice specialist, with above-average Medicare volume (top 14% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Wright-Browne experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Wright-Browne performed 59,160 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wright-Browne receive payments from pharmaceutical companies?
Yes. Dr. Wright-Browne received a total of $3,714 from 49 companies across 202 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wright-Browne's costs compare to other hematologys in Port Charlotte?
Dr. Wright-Browne's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wright-Browne) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Port Charlotte
Browse hematologys in Port Charlotte ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology